uniQure N.V. announced that the first patient has been dosed in the Phase I/II clinical trial of AMT-162 for the treatment of amyotrophic lateral sclerosis, ALS, caused by mutations in superoxide dismutase 1, SOD1, a rare, inherited and progressive motor neuron disease. EPISOD1 is a Phase I/II multi-center, open-label trial being conducted in the United States with three dose-escalating cohorts assessing the safety, tolerability and exploratory signs of efficacy of AMT-162 in individuals with SOD1-ALS.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- Nike upgraded, PayPal downgraded: Wall Street’s top analyst calls
- uniQure reinstated with an Outperform at Raymond James
- uniQure Gains FDA Orphan Drug Status for Fabry Disease Therapy
- uniQure receives Orphan Drug Designation for AMT-191 in Fabry Disease
- uniQure treatment of Fabry disease granted orphan designation